Mycovia Pharmaceuticals Inc.
Quick facts
Phase 3 pipeline
- Oteseconazole (VT-1161) · Infectious Disease
Oteseconazole is a selective inhibitor of fungal lanosterol 14α-demethylase (CYP51) that disrupts ergosterol synthesis in fungal cell membranes.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: